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Background: Cancer is a devastating type of disease. New and innovative ways to tackle cancers that have so far
proved refractive to conventional therapies is urgently needed. It is becoming increasingly clear that, in addition to
conventional therapeutics targeting by small molecules, that tumor cell metabolism presents new opportunities to
target selectively specific cancer cell populations. Metabolic defects in cancer cells can be manifested in many ways
that might not be readily apparent, such as altering epigenetic gene regulation for example.
The complex rewiring of metabolic pathways gives tumor cells a special advantage over differentiated cells, since
they deplete body stores as fuel for their growth and proliferation. Tumor metabolism looks simpler when we
consider that some enzymatic switches are in a neoglucogenic direction thereby depleting body stores. However,
these pathways may be inadequately switched on by catabolic hormones (glucagon, epinephrine and cortisol) in a
specific situation where anabolism is activated by, for example insulin released from beta pancreatic cells or IGF,
inducing mitosis and synthesis that are powered by glucose catabolism. Such a hybrid metabolic situation would
be reached if a pancreatic beta cell mechanism, mediated by GABA, failed to silence neighboring alpha cells and
delta cells. The inhibitory transmitter GABA hyperpolarizes alpha and delta cells via their GABA A receptors, and
blocks the release of glucagon and somatostatin. Alternatively, an anomaly of alpha cell channels, would lead to a
similar situation. Whatever is the alteration, anabolism fails to silence catabolism and enzymatic switches controlled
by kinases and phosphatases adopt an inadequate direction, leading to a hybrid metabolic rewiring found in
cancer. It is daring to formulate such a hypothesis as this. However, it is quite possible that the starting point in
cancer is an alteration of the endocrine pancreas, suppressing the mechanism by which beta cells silence the
neighboring alpha and delta cells, with GABA and Zn2+.Introduction
In a recent review entitled: The metabolic advantage of
tumor cells, published in Molecular Cancer [1] we ana-
lyzed a corpus of results on tumor cell metabolism de-
scribing a metabolic finality typical of cancer, in which
body stores are depleted for building up the tumor mass.
Tumor cells re-orient normal cellular processes; to create
their metabolic advantage. We showed that signaling
pathways, particularly the tyrosine kinase receptor cascade
that is targeted by oncogenes, escapes from normal
restrains. The role of a phosphatase targeted after methy-
lation over the activated kinases was discussed. We
described metabolic circuits operating in cancer, showing
how some enzymes were switched on, while others were
inhibited to create a flux of molecular building blocksCorrespondence: mauisrael@wanadoo.fr
Av. Aristide Briand 2, Bures sur Yvette 91440, France
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reproduction in any medium, provided the orbeneficial to tumor cells. The proposed model indicates
that some enzymatic switches adopt a neoglucogenic dir-
ection, while others promote oxidative glycolysis. This
model takes into account the M2 Pyruvate kinase and
PDH bottlenecks, the elevated citrate condensation and
interruptions in Krebs and urea cycles. Observations such
as the “Warburg effect” (increased lactate release), gluta-
minolysis, transaminations, poor arginine utilization, were
all included in a coherent model, helping to explain the
efficient metabolism of tumor cells [1]. In a more general
context, it is probable that toxic chemicals or internal
highly reactive products, such as superoxide are cell death
factors and the replacement of terminally differentiated
cells requires stem cells division. Mitotic cells may adopt
metabolic features giving them a selective advantage over
other cells that can be sustained by signaling network
perturbations. The resulting metabolic changes are likely to
induce epigenetic modifications that stabilize the metabolicis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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then develops; however, this is in principle a reversible
event. Then, inevitably, mutations select the most success-
ful cells, progressing with the cells towards a cancerous
phenotype. In this comment, we suggest that the complex
metabolism of tumor cells was a possible consequence of
an altered hormonal interaction, between neighboring pan-
creatic cells involving insulin and other factors released by
beta cells [2].
This comment analyzes enzymatic switches regulated
by insulin after a meal or after fasting and discusses their
potential in cancer in particular. The channels sensing
glucose; the beta cell interactions with neighboring alpha
and delta cells; as well as more distant effects will be dis-
cussed. From this critique it can be inferred that a
change in the physiology of pancreatic beta cells, failing
to inhibit alpha and delta cells, is proposed to be a pri-
mary underlying cause for cancer leading to the meta-
bolic rewiring described in the review “The metabolic
advantage of tumor cells”.
When blood glucose increases
Hyperglycemia elicits the release of insulin from pancre-
atic beta cells causing increased cellular influx of glu-
cose, thereby restoring the normal blood glucose level.
Insulin like other anabolic hormones (Figure 1A right)
acts on tyrosine kinase receptors inducing an anabolic
process, synthesizing: principally glycogen, proteins, and
lipids that are used as the building blocks of new cells.
Oxidative glycolysis powers this anabolic process by pro-
viding the necessary energy. The insulin tyrosine kinase
receptor activates complex downstream MAP and PI3
kinase routes, controlling both proliferation and metab-
olism. Lipogenesis and protein synthesis initiated by
mTOR, are not represented, they are controlled by
kinases and phosphatases exemplified by the glycogen
synthesis model. The synthesis of glycogen for example,
requires the activation of glycogen synthase by a phos-
phatase, dephosphorylating glycogen synthase. Con-
versely, the kinase GSK3 that blocks glycogen synthase
is inactivated by insulin via PKB. Pyruvate kinase (PK)
and pyruvate dehydrogenase (PDH) become active after
being dephosphorylated, and these control the entry into
the Krebs cycle. The first reaction of the cycle, the con-
densation of citrate synthase is boosted, while NADH
reduces oxygen with electrons carried by the electron
transport chain. As for the protons, they are pumped
out the mitochondria inner membrane by the respiratory
chain, and flow back through the F1-F0 ATPase to
synthesize the necessary ATP. The beta cells are able to
sense the level of glucose and release insulin; but they
also will silence the neighboring delta cells that release
somatostatin, an inhibitor on growth hormone and insu-
lin like growth factor (IGF). By inhibiting delta cells, thebeta cells reinforce the action of insulin mediated by
IGF [3,4]. Above all, the messengers released by beta
cells will also silence alpha cells releasing glucagon,
whose actions are opposite to those of insulin [5].
Effects of decreasing blood glucose
After starvation, hypoglycemia elicits the release of cata-
bolic hormones: glucagon, epinephrine, cortisol that
mobilize body stores for making nutrients: glucose and
ketone bodies (Figure 1A left). The neoglucogenic route
is fed by amino acids following the proteolysis of muscle
protein that is controlled by glucocorticoids. Alanine
coming from proteolysis is transaminated into pyruvate,
which generates oxaloacetate (OAA) via pyruvate carb-
oxylase. Following on, the enzyme phosphoenol pyruvate
carboxykinase (PEPCK) converts OAA into phosphoenol
pyruvate (PEP) building block of glucose. In this process,
it is fundamental to block PK by phosphorylation; other-
wise one would return from PEP to pyruvate. It is also
necessary to block PDH by phosphorylation, favoring the
pyruvate carboxylase reaction forming OAA, which starts
the neoglucogenic pathway. Glucose can also come from
the cleavage of glycogen, requiring the phosphorylation of
phosphorylase b into active phosphorylase a, following the
phosphorylation and activation of its specific kinase. Op-
posing this, the phosphorylation of glycogen synthase
inactivates the enzyme blocking the synthesis of glycogen.
The synthesis of other cell nutrients such as ketone
bodies requires the mobilization of lipid stores. A
hormone sensitive lipase (HSL) [6] activated by phos-
phorylation hydrolyses triglycerides giving fatty acids
forming through their beta oxidation acetyl CoA and ke-
tone bodies.
These effects depend of protein kinase A (PKA) acti-
vated by glucagon and epinephrine, they are opposite to
those of PKB stimulated by insulin signals.
The formation of glucose and ketone bodies would
fail if liver citrate synthase at the entry of the Krebs
cycle was not turned off. This occurs with a lower
oxygen reduction increasing the NADH /NAD+ ratio,
the oxidative mechanism is switched off, there is
nothing to burn. In muscles, the Krebs cycle is not
turned off, since they have to be active in stress con-
ditions. With exercise, AMP increases and activates
the Krebs cycle generating energy. In addition, AMP
stimulates an AMP-dependent kinase, which inhibits
acetyl CoA carboxylase, decreasing malonylCoA and
the synthesis of fatty acids. The decrease of malonyl-
CoA enhances the uptake of fatty acids in mitochon-
dria and the production of ketone bodies.
In neoglucogenesis, there is a protection against muscle
wasting, limiting the loss of muscle proteins and amino
acids. When large amounts of amino radicals, coming
from amino acids, enter in the urea cycle, arginine is
Figure 1 Altered pancreatic beta cell mechanism silencing alpha and delta cells. A: right, anabolic hormones: In hyperglycemia, beta
cells release insulin; tyrosine kinase receptors elicit glucose uptake, synthetic processes, cells divide. Enzymes are dephosphorylated: PK, PDH,
glycogensynthase are switched on, phosphorylase a, HSL are off; glycogen and lipids increase. These effects are induced via (PKB). Citratesynthase
is active, controlled by NADH. Anabolic beta cells turn off with GABA- Zn2+ catabolic alpha cells. A: left, catabolic hormones: In hypoglycemia
alpha cells release glucagon; adrenals release epinephrine. GS-coupled receptors activate adenylate cyclase, (PKA) phosphorylates enzymes:
phosphorylase a, is switched on, hydrolyses glycogen; glycogensynthase is off. Neoglucogenesis is activated; (PK) and PDH blockade orient the
pathway, sparing pyruvate for neoglucogenesis. Glucagon elicits (CRH) (ACTH) release triggering glucocorticoid-cortisol release from adrenals.
Cortisol induces muscle proteolysis, providing amino acids for neoglucogenesis. Citratesynthase inhibition spares oxaloacetate for
neoglucogenesis. Phosphorylated (HSL) provides fatty acids, giving ketone bodies. B: Cancer hybrid metabolism: GABA release interruption
from beta cells, cancels alpha cells inhibition, eliciting a hybrid catabolism-anabolism 1- In tumor cells, insulin induces mitosis and anabolism via
PKB; citratesynthase is activate. But glucagon and epinephrine elicit, via PKA, phosphorylation and inhibition of PK and PDH. Low GABA increases
epinephrine, inhibits somatostatin; reinforcing Growth Hormone-IGF- insulin actions.
2- In stores, catabolic hormones trigger proteolysis and lipolysis. 3- Metabolism is rewired below PK and PDH bottlenecks: tumor citratesynthase
pulls the glucose flux; receiving oxaloacetate via (PEPCK), while acetylCoA comes from ketone bodies or fatty acids oxidized in peroxisomes (their
mitochondrial transport is blocked by malonate forming tumor fatty acids via acetylCoA carboxylase). ATPcitratelyase receives the mitochondrial
citrate efflux. Diverted from neoglucogenesis, amino acids form tumor proteins, feed lactatedehydrogenase via alanine transamination.
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growth hormone, which increases the incorporation of
amino acids in muscles and protein synthesis, thereby
cancelling the loss of amino acids induced by cortisol
and catabolic hormones.In Cancer
In cancer, (Figure 1B) the enzymes PK, PDH, HSL, phos-
phorylase a, of body stores (Figure 1B left) are phosphory-
lated, via PKA activated by Gs receptors responding to
catabolic hormones (glucagon, epinephrine). This situation
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(Figure 1A left), which shows the effect of catabolic hor-
mones. Tumor cells (Figure 1B right) display a hybrid situ-
ation, the enzymes PK, PDH are phosphorylated and
blocked, via PKA and Gs receptors of tumor cells, as for
catabolic hormone effects, while HSL, phosphorylase a,
glycogen synthase are dephosphorylated, via PKB
responding to tyrosine kinase receptors activated by insu-
lin and IGF as in the case of anabolic hormone actions
represented (Figure 1A right). In contrast to the “catabolic
hormone situation” (Figure 1A left) tumor cells have an
active citrate synthase, pulling the glycolytic flux in the
glycolytic direction, to feed the condensation reaction of
the Krebs cycle. How will tumor glycolysis reach the entry
of the Krebs cycle and overcome the blockade of PK and
PDH? This is not really a problem, since the enzyme
PEPCK is fully reversible, and converts PEP, accumulated
above the PK bottleneck, into OAA. The latter, is con-
densed with acetyl CoA coming from the mobilization of
lipid stores (Figure 1B left and right). In tumors, the pyru-
vate resulting from alanine transamination gives lactate
(Warburg effect) and NAD+ required for glycolysis to
proceed at the glyceraldehydephosphate dehydrogenase
step (Figure 1B left and right). It follows then that the sup-
ply of pyruvate to pyruvate carboxylase is interrupted.
However, in tumors, there is a downstream blockade in the
Krebs cycle, below the level of citrate synthase, favoring
the efflux of citrate from mitochondria. This citrate is then
cleaved by cytosolic ATP citratelyase, providing acetyl CoA
for fatty acids and triglyceride synthesis, while the other
enzyme product, OAA, drives the transaminases in the dir-
ection found in neoglucogenesis, which then consume
amino acids and glutamine. In tumors these amino acids
are diverted for making proteins rather than feeding the
neoglucogenic pathway (Figure 1B left and right). As for
the urea cycle it is active in tumors, as it is the case in neo-
glucogenesis, but the argininosuccinate synthase step is
blocked.
The metabolic inference here is that the rewiring
found in cancer consumes body stores, not for making
glucose or ketone bodies, but for building the tumor
while burning glucose (Figure 1B left and right).
Anabolic hormones switch off catabolic hormones by a
specific mechanism
Anabolic or catabolic situations
Figure 1A shows an overview of catabolic or anabolic hor-
monal effects on metabolism, where the selection between
these processes is under the control of pancreatic beta
cells, that hold the keys for switching on anabolism and
switching off catabolism. Here, an interruption of the beta
cell switch off system is represented, which predicts the
metabolic changes observed in cancer (Figure 1B left and
right). The metabolism of tumor cells has been describedin detail [1]. The simplest summary, considers that part of
the switches are in the neoglucogenic-ketogenic direction,
depleting stores, as if the catabolic hormones: glucagon,
epinephrine or cortisol where at work. While tumor cell
switches responding to anabolic hormones: insulin and
IGF, support anabolism, powered by oxidative glycolysis
that is driven by an active citrate synthase condensation.
However, even in tumor cells PK and PDH switches are
off responding to catabolic hormones.
We do know that the tyrosine kinase receptor acti-
vated by insulin, stimulates oxidative glycolysis and trig-
gers cell proliferation and anabolic processes. The
cascades of signals that are activated are precisely tar-
geted by many oncogenes. We also know that pancreatic
beta cells that release insulin have to turn off the neigh-
boring alpha cells releasing glucagon, with opposing
actions taking place in starvation, when glucose is
scarce. We should also bear in mind that glucagon, simi-
larly to epinephrine, acts on G protein coupled receptors
stimulating adenylate cyclase, the (Gs) type, increasing
cAMP production. This in turn activates protein kinase
A (PKA), which phosphorylates the set of enzymes (PK,
PDH, HLP, phosphorylase a) mentioned above for mak-
ing nutrients while mobilizing stores. The beta cell
blocks these opposite glucagon and epinephrine effects
[2]. The insulin beta cell granules release their contents
in the extracellular space when beta cells are depolarized
after sensing glycemia. Choline derivatives are also
released; whose lipotropic action and role is discussed
elsewhere [1] [7]; they help the methylation of a phos-
phatase such as PP2A [8]. After methylation, it is
targeted over specific sites, and counteracts the kinases
activated by insulin tyrosine kinase signals. The insulin
containing granules also contain other components such
as Zn2+ [9]. Moreover, beta cells are rich in GABA that
is synthesized by the enzyme glutamate decarboxylase,
which has been shown to be an autoantigen in insulin-
dependent diabetes [10]. The release of GABA from beta
cells has been well documented [11]. This transmitter
acts on GABA A receptors found on the neighboring
alpha and delta cells, triggering a chloride influx, which
hyperpolarizes alpha cell and delta cells, blocking the
release of glucagon and somatostatin [2,3]. The release
of Zn2+ acts in synergy with GABA, blocking glucagon
release from alpha cells [9]. At some distance, the GABA
released with insulin, inhibits the release of epinephrine
from adreno-medulla cells [12] that are activated by
acetylcholine, but inhibited by GABA. In this way, the
beta cell activates anabolism and oxidative glycolysis
with insulin and inhibits with GABA the alpha cell, and
the release of glucagon, switching off neoglucogenesis
and lipolysis. The enzymes controlled by glucagon or
epinephrine (PK, PDH, HLP phosphorylase a,) are no
longer phosphorylated, since glucagon and epinephrine
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coupled receptors, adenylate cyclase and PKA.
Glucose controls pancreatic cell ion channels and hormone
release
Alpha, beta and delta pancreatic cells, sense the concen-
tration of glucose via the levels of ATP in their cytosol;
an increase of ATP closes membrane K+ channels that
are inhibited by ATP (K ATP). This has the effect of de-
polarizing beta cells, whose electrical activity, depends
greatly on L type calcium channels, and the influx of
calcium elicits the release of insulin, GABA and other
substances. These L type calcium channels are not inac-
tivated by elevated depolarization, as a response to high
glucose concentrations. The alpha cells that release glu-
cagon are equipped with high affinity glucose transpor-
ters that start working at low glucose levels. The
intracellular increase of ATP still has the effect of
closing the K ATP channels, but in alpha cells, the
depolarization triggers the activity of voltage dependent
sodium channels and calcium channels of the T and N
types, which work at a low membrane depolarization,
elicited by moderate changes in glucose levels. These
channels are desensitized when the membrane
depolarization is elevated, such as occurs if K ATP chan-
nels are completely closed due to sensing of elevated
glucose levels [13].The release of GABA from the beta
cells inhibits the glucagon release from alpha cells that
presumably occurs before they get self-inhibited at high
glucose levels. As for the delta cells releasing somato-
statin, the K ATP channel sensors of glucose, elicits their
depolarization. The resulting electrical activity depends
of a variety of channels, including the L type calcium
channel, as for beta cells, but also the P and Q types cal-
cium channels that are activated at high-voltage. Release
of GABA from beta cells inhibits somatostatin release
from delta cells that are equipped with GABA A recep-
tors [14]. If the release of GABA from beta cells
decreases, glucagon release, and epinephrine release
from adrenal medulla in turn increases, with the result-
ing epinephrine block of the delta cell somatostatin
release [15].
It is probable that in resting conditions large amounts
of GABA leak out from beta cells, keeping silent the
alpha cells, hyperpolarized through their GABA A recep-
tors. A decrease of glucose opens K ATP channels, the
beta cells become hyperpolarized, which decreases the
resting efflux of GABA, the resultant depolarization of the
alpha cell being greater than the hyperpolarization elicited
by its own K ATP channels. The depolarization of the alpha
cell triggers their electrical activity and the calcium
dependent release of glucagon correcting hypoglycemia.
The situation is different in hyperglycemia; in the beta cell,
hyperglycemia closes K ATP channels, the depolarizationeliciting the release of insulin, the release of GABA being
essentially a resting release, nothing much changes. The
alpha cells also sense hyperglycemia with K ATP channels
but in contrast to beta cells, their electrical activity
depends on channels that are desensitized at elevated
membrane depolarization, the alpha cell is electrically si-
lent at high glucose, and glucagon is not released.
Can tumor metabolism be fully explained?
The first possibility is that beta cells normally release in-
sulin, but the release of GABA or Zn2+, is interrupted
(as they are not necessarily simultaneous). Hence, insu-
lin supports anabolism, while oxidative glycolysis driven
by citrate synthase provides the energy for synthesizing
new materials for dividing cells. The decreased release of
GABA and Zn2+, will fail to block glucagon release from
the alpha cells, while at some distance, the decrease of
GABA enhances epinephrine release from adrenal cells.
Glucagon and epinephrine act on Gs receptors, mediating
PKA activation via adenylate cyclase and the phosphoryl-
ation of enzymes such as PK, PDH, HLP, phosphorylase a,
that in a similar manner to starvation mobilizes body
stores. But here, however, insulin has already activated
synthetic processes that require energy and an active oxi-
dative glycolysis, cells burn glucose while depleting stores!
This situation is beneficial to the dividing cells that
respond to tyrosine kinase signals. The result is that tumor
cells mobilize body stores in anabolic and glycolytic condi-
tions, to build the tumor mass using body stores, the
metabolic rewiring linked to the blockade of PK and PDH
in tumor cells and in body stores is schematized in
Figure 1B, in tumor cells PK and PDH are inactivated via
PKA signals, while the other tumor enzymes are boosted
via PKB. Moreover, the release of glucagon acts on central
neurons releasing corticotropin-releasing hormone (CRH),
which increases ACTH release [16]. The latter, triggers the
release of glucocorticoids (cortisol) from the adrenal cortex
that binds to steroid receptors in muscles inducing prote-
olysis. Cortisol is a glucocorticoide and should support
neoglucogenesis, but again, citrate synthase is abnormally
active in tumor cells and pulls the flux in the glycolytic
direction. The anti-inflammatory effect of glucocorticoid
may also attenuate an immune reaction against nascent
tumor cells. The result is a metabolism with a mix of
neoglucogenic and glycolytic features, giving a selective ad-
vantage to tumor cells.
It is interesting to mention that PKA is involved in
mRNA splicing mechanisms, controlling the selection of
exons. In tumors, the embryonic form of pyruvate
kinase, PK M2 with exon 10, replaces the adult enzyme
PK M1 with exon 9 [17] and [18].
In summary, a decrease of GABA or Zn2+ contents and
release from beta cells, would fail to inhibit glucagon and
catabolic hormones. In addition, the central action of
Israël Molecular Cancer 2012, 11:63 Page 6 of 7
http://www.molecular-cancer.com/content/11/1/63glucagon [16] increases growth hormone release and then
IGF, which boosts the insulin effect. Somatostatin release
from delta cells cannot attenuate Growth Hormone-IGF
actions since the increase of epinephrine, resulting from
the lower GABA released, blocks the delta cells [15], epi-
nephrine instead does the job for GABA. In addition, a
low choline release impairs the carboxy methylation of
leucine 309 in the catalytic unit of PP2A phosphatase, thus
the regulatory units are no longer recruited, removing the
brake over activated kinases.
There is a second possibility for reaching a similar
metabolic situation: an intrinsic alteration of alpha cell
channels, which would keep them active at elevated glu-
cose levels, when insulin is released from beta cells. The
paracrine effects and more distant effects of GABA and
Zn2+ and other substances that are released with insulin
will still operate.
Conclusion and inferences for future intervention
strategies
In the scenario outlined herein, cancer may then result
from a deficient composition of beta cell granules, or vesi-
cles, or of GABA synthesized in their cytoplasm. The
cocktail of factors released: low Zn2+, low GABA, normal
insulin-corrects glycemia, but fails to inhibit the other
pancreatic cells; the alpha cell, continues to release gluca-
gon. In addition, at some distance, the adrenals will release
more epinephrine. In the hypothalamus and hypophysis,
glucagon increases CRH and ACTH, the latter triggers the
release of cortisol from the adrenal cortex, cortisol mobi-
lizes muscle protein stores, supporting the action of epi-
nephrine and glucagon in conditions where insulin is
secreted without its partners that block opposite actions.
Several experiments can be envisioned to test this pro-
vocative model. One may analyze the composition of beta
cell granules and vesicles [19] and measure the GABA and
glutamate decarboxylase. There are also histochemical
procedures for Zn2+. The pharmacology of GABA recep-
tors is well known; can we transform cells with com-
pounds increasing glucagon release and catabolic
hormones, in hyperglycemic conditions that activate insu-
lin release? We may also manipulate the effects of cata-
bolic hormones using known agonists, antagonists or
toxins, changing cAMP and PKA actions, with the aim of
such an experiment being to elicit a tumorigenic mechan-
ism. Here, one would try to phosphorylate directly the
enzymes mentioned, with compounds increasing cAMP,
and then activate in a local population of cells, their insu-
lin tyrosine kinase receptor signaling, their oxidative me-
tabolism and citrate synthase. Whether these cells become
tumor cells depleting body stores for their benefit is a key
question. One may also study the effects of bicuculine, an
antagonist of GABA A receptors, in hyperglycemic condi-
tions that elicit an insulin release. The PP2A brake oversignaling kinases might also be removed using choline up-
take inhibitors, anti folates, as this should inhibit the car-
boxy methylation of PP2A. We have in a previous review
[1] listed compounds acting on downstream targets asso-
ciated to cancer, citrate [20] hydroxycitrate, lipoid acid,
that gave interesting results [21], a useful low arginine diet
[22] and other targets were discussed. In this comment,
we have possibly identified an upstream target that leads
to cancer. If further experiments demonstrated that this is
indeed the case, the starting point of cancer would be a
specific alteration of Langerhans cells in the endocrine
pancreas; it is not insulin that is decreased but its partners,
GABA, Zn2+ and choline, creating conditions that appear
inevitably to lead to tumor formation.
Finally, it may be interesting to increase the GABA con-
tent of beta cells, possibly by transfecting them with a plas-
mid encoding glutamate decarboxylase, since this
autoantigen gives a type 1 diabetes. A stimulation of glu-
tamate decarboxylase with vitamin B6 also deserves investi-
gation. Some time ago we described a chemiluminescent
GABA assay that would be useful for monitoring this
transmitter [23]. As for Zn2+, it deserves to be studied in
this context, as well as the glutamatergic transmission in
the pancreas. Phosphatases are particularly interesting,
choline, B12, folate, would support a protective methylation
of PP2A, as discussed in other works. At the very least, this
comment suggests new approaches and possible experi-
ments in the field of cancer development and treatment.
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